pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

FDA releases weekly update on user fee letters and new HHS regulatory agenda

Aug 14, 2026·read at raps ↗RegulatoryNeutral

The FDA's latest weekly briefing highlighted the release of user fee commitment letters, which outline the agency's financial planning for upcoming fiscal periods.

It also introduced a new regulatory agenda from the Department of Health and Human Services, signaling upcoming policy priorities for drug and device oversight.

The update serves as a concise source for professionals tracking regulatory changes, linking to relevant documents and commentary from industry observers.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “This Week at FDA: User fee commitment letters, new HHS regulatory agenda, and more”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoFDA finalizes guidance on formal meetings with drug and biologics sponsorsraps
  • 1d agoIndustry groups seek clarity, flexibility in manufacturer-payor communications guidanceraps
  • 2d agoRecon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in Chinaraps
  • 2d agoEuro Roundup: Notified bodies call for access to Eudamed to enable move to risk-based oversightraps
  • 2d agoPDUFA VIII: FDA outlines goals, program enhancements in commitment letterraps